RIA
ALNY icon

Regal Investment Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Regal Investment Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$732K Sell
2,432
-259
-10% -$78.1K 0.04% 384
2026
Q1 		$890K Sell
2,691
-23
-0.8% -$7.83K 0.05% 316
2025
Q4 		$1.08M Buy
2,714
+12
+0.4% +$5.31K 0.06% 261
2025
Q3 		$1.23M Sell
2,702
-204
-7% -$83.1K 0.08% 228
2025
Q2 		$948K Hold
2,906
– – 0.07% 246
2025
Q1 		$785K Sell
2,906
-252
-8% -$64.8K 0.06% 250
2024
Q4 		$743K Sell
3,158
-19
-0.6% -$5K 0.06% 269
2024
Q3 		$874K Sell
3,177
-171
-5% -$44.5K 0.06% 265
2024
Q2 		$814K Buy
3,348
+132
+4% +$20.8K 0.05% 281
2024
Q1 		$481K Buy
3,216
+251
+8% +$41.9K 0.03% 371
2023
Q4 		$568K Buy
2,965
+162
+6% +$27.6K 0.04% 303
2023
Q3 		$496K Buy
2,803
+8
+0.3% +$1.53K 0.04% 297
2023
Q2 		$531K Buy
2,795
+853
+44% +$169K 0.04% 284
2023
Q1 		$389K Buy
+1,942
New +$408K 0.03% 336

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Regal Investment Advisors's ALNY Position: Q2 2026 in Review

Regal Investment Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 9.6% in Q2 2026, selling an estimated $78.1K and leaving 2,432 shares worth $732K. The position accounts for 0.04% of the portfolio, ranked #384.

Regal Investment Advisors first reported a position in ALNY in Q1 2023 and has held it in 14 quarters since. The position peaked at $1.23M in Q3 2025. 791 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Regal Investment Advisors held 2,432 shares of Alnylam Pharmaceuticals worth $732K as of Q2 2026.
  • Regal Investment Advisors sold 259 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $78.1K.
  • Alnylam Pharmaceuticals made up 0.04% of Regal Investment Advisors's portfolio in Q2 2026, its #384 holding.
  • Regal Investment Advisors first reported a position in Alnylam Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
  • Regal Investment Advisors's Alnylam Pharmaceuticals position peaked at $1.23M in Q3 2025.
  • 791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Regal Investment Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.